|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-27.40/-1.12
|
企业价值
2.65M
|
资产负债 |
每股账面净值
-0.15
|
现金流量 |
现金流量率
--
|
损益表 |
收益
420.00K
|
每股收益
0.06
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/12 05:59 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib. |